BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9158517)

  • 1. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?
    Haukaas S; Roervik J; Halvorsen OJ; Foelling M
    Br J Urol; 1997 May; 79(5):770-6. PubMed ID: 9158517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate.
    Bruwer G; Heyns CF; Allen FJ
    Eur Urol; 1999; 35(3):223-7. PubMed ID: 10072624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
    Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
    Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
    Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
    Lorente JA; Valenzuela H; Morote J; Gelabert A
    Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.
    Lai MH; Luk WH; Chan JC
    Urol Oncol; 2011; 29(3):275-9. PubMed ID: 19734069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
    Wymenga LF; Boomsma JH; Groenier K; Piers DA; Mensink HJ
    BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram.
    Stokkel M; Zwinderman A; Zwartendijk J; Pauwels E; van Eck-Smit B
    Eur J Nucl Med; 1997 Oct; 24(10):1215-20. PubMed ID: 9323261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer.
    Gleave ME; Coupland D; Drachenberg D; Cohen L; Kwong S; Goldenberg SL; Sullivan LD
    Urology; 1996 May; 47(5):708-12. PubMed ID: 8650870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate?
    Wolff JM; Zimny M; Borchers H; Wildberger J; Buell U; Jakse G
    Eur Urol; 1998; 33(4):376-81. PubMed ID: 9612680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
    Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
    Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer.
    Rudoni M; Antonini G; Favro M; Baroli A; Brambilla M; Cardani G; Ciardi L; Sacchetti GM; Inglese E
    Eur J Nucl Med; 1995 Mar; 22(3):207-11. PubMed ID: 7540551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can prostate-specific antigen levels predict bone scan evidence of metastases in newly diagnosed prostate cancer?
    Vijayakumar V; Vijayakumar S; Quadri SF; Blend MJ
    Am J Clin Oncol; 1994 Oct; 17(5):432-6. PubMed ID: 7522394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
    Oommen R; Geethanjali FS; Gopalakrishnan G; Chacko N; John S; Kanagasabapathy AS; Roul RK
    Br J Radiol; 1994 May; 67(797):469-71. PubMed ID: 7514940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
    Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
    JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
    Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
    Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.